Drug Profile
Adalimumab biosimilar - Boehringer Ingelheim
Alternative Names: Adalimumab-adbm; BI-695501; CyltezoLatest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
Most Recent Events
- 10 Nov 2023 Pooled adverse events data from the phase III VOLTAIRE-RA and VOLTAIRE-RAext, VOLTAIRE-CD, and VOLTAIRE-PsO and VOLTAIRE-X trials in Rheumatoid arthritis, Crohn’s disease, and Chronic plaque psoriasis presented at the American College of Rheumatology (ACR-2023)
- 10 Nov 2022 Pooled immunogenicity data from a phase III VOLTAIRE-RA, VOLTAIRE-CD and VOLTAIRE-PsO trials in Rheumatoid arthritis, Crohn’s disease, and Chronic plaque psoriasis presented at the American College of Rheumatology (ACR-2022)
- 29 Aug 2022 Boehringer Ingelheim completes a phase I pharmacokinetics trial (In volunteers) in USA (SC, injection) (NCT05203289)